In short
Clinical trials are studying Savolitinib in people with certain cancers, mainly non-small cell lung cancer and papillary renal cell carcinoma. These studies are looking at how well it works, how safe it is in combinations, and whether it can improve outcomes in specific patient groups.
Key points
- Savolitinib is being studied in clinical trials for non-small cell lung cancer and papillary renal cell carcinoma. The lung cancer studies focus mostly on people with EGFR changes and MET-positive disease, especially after treatment with osimertinib. The kidney cancer study looks at MET-driven, unresectable, locally advanced or metastatic papillary renal cell carcinoma. The trials include Phase 2 and Phase 3 research, so they are testing both early signs of benefit and larger comparisons with standard care. Main outcomes include overall response rate, progression-free survival, and disease control rate. Most studies test Savolitinib in combination with other treatments rather than by itself.
Overview of the Savolitinib trials
The trial data show Savolitinib being studied in people with cancer, mainly non-small cell lung cancer (NSCLC) and papillary renal cell carcinoma (PRCC).
These are interventional studies, which means the researchers give a study treatment and then measure how the cancer responds.
Most of the studies test Savolitinib with another cancer medicine, not as a stand-alone treatment.
Non-small cell lung cancer studies
Two Phase 2 trials and one Phase 3 trial focus on NSCLC that has EGFR mutations and MET changes such as amplification or overexpression.
One Phase 2 study looks at people whose NSCLC got worse after initial treatment with osimertinib, and it measures overall response rate, which means how many tumors shrink or disappear during treatment.
The Phase 3 lung cancer study compares Savolitinib plus osimertinib with platinum-doublet chemotherapy, which is a common chemotherapy combination that uses two drugs together.
That Phase 3 study measures progression-free survival, which is the time before the cancer gets worse or the person dies from any cause.
A completed Phase 2 study called PIONeeR also included Savolitinib as one of several immune-oncology strategies in advanced NSCLC with PD-1/PD-L1 resistance, and it measured disease control rate at 12 weeks.
In simple terms, this means the study checked how many people had their cancer kept stable or better after 12 weeks.
Papillary renal cell carcinoma study
One Phase 3 study, SAMETA, is in people with MET-driven, unresectable, locally advanced or metastatic papillary renal cell carcinoma.
This study compares Savolitinib plus durvalumab with sunitinib and durvalumab monotherapy, and it measures progression-free survival by blinded independent central review, which means the scans are checked by reviewers who are not part of the treatment team.
The study goal is to see whether Savolitinib plus durvalumab works better than the comparison treatment for this kidney cancer group.
Trial phases and main endpoints
The trial set includes Phase 2 and Phase 3 research.
Phase 2 studies usually look for early signs that a treatment may work, while Phase 3 studies compare a treatment with standard care in larger groups.
The main endpoints in these studies are overall response rate, progression-free survival, and disease control rate.
An endpoint is the main result the researchers want to measure, such as tumor shrinkage or time until the cancer gets worse.
Who the trials are designed for
The NSCLC trials focus on people with locally advanced or metastatic disease, which means the cancer has grown beyond its original site and may have spread.
Several lung cancer studies require EGFR-mutated and MET-positive or MET-amplified/overexpressed tumors, so the cancer must have certain lab features to fit the study.
The PIONeeR study enrolled advanced NSCLC patients with resistance to PD-1 or PD-L1 immunotherapy, meaning their cancer had stopped responding to those treatments.
The SAMETA study is for people with MET-driven PRCC that is unresectable and locally advanced or metastatic.
What the studies measure
Overall response rate (ORR) checks how many people have a measurable tumor response, such as a partial or complete shrinkage.
Progression-free survival (PFS) shows how long the cancer stays from getting worse after treatment starts.
Disease control rate (DCR) includes people whose cancer shrinks or stays stable for a set period, such as 12 weeks in the PIONeeR study.
These measures help researchers compare Savolitinib combinations with other treatments and decide whether the study treatment is worth further testing.